- Patents Court confirms that administrative error means Genentech’s ranibizumab SPC will lapse earlier than the maximum permitted period of duration (Master Data v Comptroller and Genentech v Comptroller)
- What are the practical implications of this case?
- What was the background?
- The Hearing Officer’s decision
- What did the court decide?
- Master Data’s appeal
- Genentech’s appeal
- Case details
Life Sciences analysis: The Patents Court has dismissed Genentech and Master Data Centre’s appeal against the Comptroller General of Patents’ decision that Genentech’s Supplementary Protection Certificate (SPC) for ranibizumab will lapse on 2 April 2020, ie earlier than the maximum permitted period of duration, due to Master Data (Genentech’s patent administration company) making a mistake and only requesting and paying for a two-year term, rather than the desired four-year term.
Sign in or take a trial to read the full analysis.
To continue reading this news article, as well as thousands of others like it, sign in to LexisPSL or register for a free trial